日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer

多组学分析能够深入了解小细胞肺癌的异质性、微环境特征和生物标志物图谱。

Xie, Mingchao; Vuko, Miljenka; Saran, Shashank; Liu, Siyu; Chambers, Andrew G; Baakza, Hana; Angell, Helen K; Ng, Felicia; Gay, Carl M; Cardnell, Robert J; Segerer, Felix J; Andoni, Alma; Rodriguez-Canales, Jaime; Waring, Paul M; Schick, Markus; Barrett, J Carl; Byers, Lauren A; Fabbri, Giulia

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

DNA损伤反应特征与广泛期小细胞肺癌的一线化疗反应和肿瘤演变途径相关

Morris, Benjamin B; Heeke, Simon; Xi, Yuanxin; Diao, Lixia; Wang, Qi; Rocha, Pedro; Arriola, Edurne; Lee, Myung Chang; Tyson, Darren R; Concannon, Kyle; Ramkumar, Kavya; Stewart, C Allison; Cardnell, Robert J; Wang, Runsheng; Quaranta, Vito; Wang, Jing; Heymach, John V; Nabet, Barzin Y; Shames, David S; Gay, Carl M; Byers, Lauren A

The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC

靶向TRAF2和NCK相互作用蛋白激酶对c-MYC高表达小细胞肺癌抗肿瘤效应和肿瘤免疫微环境的影响

Tanimoto, Azusa; Ramkumar, Kavya; Stewart, C Allison; Zhang, Bingnan; Concannon, Kyle; Cardnell, Robert J; Shen, Li; Wang, Qi; Wang, Jing; Gay, Carl M; Byers, Lauren Averett

YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.

YAP1 状态定义了 LCNEC 的两种内在亚型,它们具有不同的分子特征和治疗脆弱性

Stewart C Allison, Diao Lixia, Xi Yuanxin, Wang Runsheng, Ramkumar Kavya, Serrano Alejandra G, Tanimoto Azusa, Rodriguez B Leticia, Morris Benjamin B, Shen Li, Zhang Bingnan, Yang Yan, Hamad Samera H, Cardnell Robert J, Duarte Alberto Jr, Sahu Moushumi, Novegil Veronica Y, Weissman Bernard E, Frumovitz Michael, Kalhor Neda, Solis Soto Luisa, da Rocha Pedro, Vokes Natalie, Gibbons Don L, Wang Jing, Heymach John V, Glisson Bonnie, Byers Lauren Averett, Gay Carl M

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

简报:EGFR突变型非小细胞肺癌小细胞转化的全面临床基因组学分析揭示潜在治疗靶点

Zhang, Bingnan; Lewis, Whitney; Stewart, C Allison; Morris, Benjamin B; Solis, Luisa M; Serrano, Alejandra; Xi, Yuanxin; Wang, Qi; Lopez, Elyse R; Concannon, Kyle; Heeke, Simon; Tang, Ximing; Raso, Gabriela; Cardnell, Robert J; Vokes, Natalie; Blumenschein, George; Elamin, Yasir; Fosella, Frank; Tsao, Anne; Skoulidis, Ferdinandos; Hume, Celyne Bueno; Sasak, Koji; Lewis, Jeff; Rinsurongkawong, Waree; Rinsurongkawong, Vadeerat; Lee, Jack; Tran, Hai; Zhang, Jianjun; Gibbons, Don; Vaporciyan, Ara; Wang, Jing; Park, Keunchil; Heymach, John V; Byers, Lauren A; Gay, Carl M; Le, Xiuning

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

STING通路表达可识别具有免疫反应表型的非小细胞肺癌

Della Corte, Carminia M; Sen, Triparna; Gay, Carl M; Ramkumar, Kavya; Diao, Lixia; Cardnell, Robert J; Rodriguez, Bertha Leticia; Stewart, C Allison; Papadimitrakopoulou, Vassiliki A; Gibson, Laura; Fradette, Jared J; Wang, Qi; Fan, Youhong; Peng, David H; Negrao, Marcelo V; Wistuba, Ignacio I; Fujimoto, Junya; Solis Soto, Luisa M; Behrens, Carmen; Skoulidis, Ferdinandos; Heymach, John V; Wang, Jing; Gibbons, Don L; Byers, Lauren A

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers

针对耐药恶性肿瘤的差异敏感性分析(DISARM)可识别铂类耐药癌症的常见候选疗法

Gay, Carl M; Tong, Pan; Cardnell, Robert J; Sen, Triparna; Su, Xiao; Ma, Jun; Bara, Rasha O; Johnson, Faye M; Wakefield, Chris; Heymach, John V; Wang, Jing; Byers, Lauren A

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

一项随机、双盲、II期研究,评估替莫唑胺联合维利帕尼或安慰剂治疗复发敏感或难治性小细胞肺癌患者的疗效

Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M; Dowlati, Afshin; Hann, Christine L; Chiappori, Alberto; Owonikoko, Taofeek K; Woo, Kaitlin M; Cardnell, Robert J; Fujimoto, Junya; Long, Lihong; Diao, Lixia; Wang, Jing; Bensman, Yevgeniva; Hurtado, Brenda; de Groot, Patricia; Sulman, Erik P; Wistuba, Ignacio I; Chen, Alice; Fleisher, Martin; Heymach, John V; Kris, Mark G; Rudin, Charles M; Byers, Lauren Averett

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

TTF1 和 cMYC 蛋白的表达定义了小细胞肺癌的不同分子亚群,这些亚群对 Aurora 激酶抑制剂、DLL3 靶向治疗和其他靶向疗法具有独特的敏感性。

Cardnell, Robert J; Li, Lerong; Sen, Triparna; Bara, Rasha; Tong, Pan; Fujimoto, Junya; Ireland, Abbie S; Guthrie, Matthew R; Bheddah, Sheila; Banerjee, Upasana; Kalu, Nene N; Fan, You-Hong; Dylla, Scott J; Johnson, Faye M; Wistuba, Ignacio I; Oliver, Trudy G; Heymach, John V; Glisson, Bonnie S; Wang, Jing; Byers, Lauren A

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

源自患者的泛癌EMT特征可识别上皮间质转化后的整体分子改变和免疫靶点富集

Mak, Milena P; Tong, Pan; Diao, Lixia; Cardnell, Robert J; Gibbons, Don L; William, William N; Skoulidis, Ferdinandos; Parra, Edwin R; Rodriguez-Canales, Jaime; Wistuba, Ignacio I; Heymach, John V; Weinstein, John N; Coombes, Kevin R; Wang, Jing; Byers, Lauren Averett